Cannabis Stocks Surge 20% on Rescheduling: What Investors Should Know

The Rally Everyone Was Waiting For

On April 23, 2026, the Department of Justice formally reclassified state-licensed medical marijuana from Schedule I to Schedule III, and cannabis stocks did exactly what the market had been pricing in for months—they surged.

Canopy Growth (CGC), Curaleaf (CRLBF), and Trulieve (TCNNF) each jumped roughly 20 percent. Green Thumb Industries (GTBIF) rallied over 13 percent. Tilray (TLRY) climbed 9.3 percent. Aurora Cannabis rose 6 percent in pre-market trading alone. The AdvisorShares Pure US Cannabis ETF (CNBS) advanced approximately 20 percent, reflecting broad-based enthusiasm across the sector.

It was the kind of day cannabis investors had been dreaming about for years. But now that the initial euphoria has settled, the question every investor needs to answer is: what comes next?

Why the Market Reacted So Strongly

The rally wasn't just about symbolism. Rescheduling medical cannabis to Schedule III triggers concrete financial benefits that flow directly to company bottom lines.

The most significant is the neutralization of IRS Section 280E, which has prevented cannabis businesses from deducting standard operating expenses from their federal taxes. Under 280E, effective tax rates for cannabis companies routinely reached 60 to 80 percent. With medical cannabis no longer classified as a Schedule I substance, qualifying operators can immediately begin claiming normal business deductions—rent, payroll, utilities, marketing, and equipment.

For multi-state operators generating hundreds of millions in revenue, the cash flow improvement is transformational. Analysts estimate that the 280E relief alone could increase industry-wide free cash flow by billions of dollars annually.

The Bull Case

The arguments for continued upside in cannabis stocks are substantial.

The June 29 DEA hearing could extend Schedule III classification to all cannabis, including recreational. If that happens, the entire industry—not just medical operators—would benefit from 280E tax relief, further improving profitability and cash flow projections.

Improved cash flow opens the door to capital reinvestment, debt reduction, and potential dividend programs. Companies that have been surviving under punitive tax treatment can now invest in growth, technology, and operational efficiency.

Banking access, while not automatically guaranteed by rescheduling, becomes significantly easier. Financial institutions face lower regulatory risk in serving Schedule III businesses, and the SAFE Banking Act—which has passed the House multiple times but stalled in the Senate—may find renewed momentum.

Market research firm BDSA projects $47 billion in legal cannabis sales in 2026, with continued growth expected as more states legalize and existing markets mature. The industry's revenue trajectory is upward regardless of the rescheduling outcome—but rescheduling accelerates the timeline.

The Bear Case

Tempting as it is to ride the wave, cannabis stocks carry significant risks that the April rally doesn't eliminate.

Cannabis remains federally illegal. Schedule III classification does not legalize the substance—it reduces restrictions and penalties. Interstate commerce remains prohibited, and federal enforcement discretion could change with any future administration. This legal ambiguity continues to deter institutional investors and limit access to capital markets.

The dual-license complication creates near-term uncertainty. Companies operating in both medical and recreational markets can only claim 280E relief on their medical operations until the broader rescheduling question is resolved. The IRS guidance on expense apportionment between medical and recreational activities hasn't been issued yet, creating accounting risk.

Overvaluation is a real concern. Cannabis stocks have historically been subject to speculative bubbles driven by regulatory catalysts. The sector experienced dramatic boom-and-bust cycles in 2018, 2021, and 2024. Investors who bought at previous peaks—particularly during Canada's legalization euphoria in 2018—are still underwater in many cases.

Competition continues to intensify. Legal markets in mature states like Colorado, Oregon, and California have experienced sustained price compression as supply outpaces demand. Not all operators will survive even with improved tax treatment.

Which Companies Are Best Positioned?

The rescheduling benefits aren't distributed equally across the cannabis sector. Several factors determine which companies stand to gain the most.

Companies with strong medical-license portfolios receive immediate 280E relief and see the most direct impact on their financials. Multi-state operators with licenses across multiple medical markets—Trulieve, Curaleaf, and Green Thumb among them—are structurally advantaged in this phase.

Vertically integrated operators that control cultivation, processing, and retail capture more of the value chain and benefit from deducting expenses across all functions, rather than just at the retail level.

Companies with manageable debt loads can use the improved cash flow for growth rather than servicing existing obligations. Heavily leveraged operators may see their tax savings absorbed by debt payments, limiting the upside for shareholders.

Cash-flow positive companies—those already generating positive operating cash flow under the punitive 280E regime—will see the largest proportional improvement. A company that was barely profitable under 80 percent effective tax rates could become robustly profitable under normal taxation.

The Smart Approach

For investors considering cannabis exposure in the wake of the rescheduling rally, several principles apply.

Diversification within the sector is wise. Individual cannabis companies carry company-specific risks—management issues, regulatory exposure in specific states, balance sheet problems—that can overwhelm even favorable macro trends. ETFs like CNBS or MSOS provide broader exposure to the sector's tailwinds while reducing single-stock risk.

Time horizon matters enormously. The cannabis industry's long-term trajectory is overwhelmingly positive, but short-term volatility is extreme. Investors who need liquidity within 12 to 18 months should be cautious about current entry points after a 20 percent rally.

Watch the June 29 hearing closely. The outcome will determine whether the current rally has legs or whether the industry enters another period of regulatory uncertainty. A favorable ruling extending Schedule III to all cannabis could drive another significant leg up; an unfavorable one could trigger a sharp correction.

The cannabis rescheduling rally is real, grounded in concrete financial improvements, and potentially the beginning of a larger re-rating of the sector. But in an industry where hype has burned investors before, disciplined analysis matters more than ever.

To see which operators benefit most from the rescheduling tailwind, browse Budpedia's cannabis dispensary directory covering 7,400+ verified retailers — including the multi-state operators driving the rally — with location-level menus across every legal state.